$Semler Scientific (SMLR.US)$ Listed in 2021, revenue, opera...

Listed in 2021, revenue, operating profit, and net income increased by 37.4%, 21.8%, and 23% respectively in the year of listing. In 2022, revenue increased by 6.9%, while operating profit and net income decreased by 11.5% and 16.8% respectively. The decline in profit was mainly caused by a significant increase in operating expenses.

In Q1 2023, revenue increased by 30%, operating profit increased by 58.7%, and net income increased by 47.9%, returning to double-digit growth.

The balance sheet shows that the proportion and growth rate of accounts receivable and inventory are normal, with no significant interest-bearing liabilities.

Except for a large-scale investment outflow in 2022, the net operating cash flow has been significantly higher than the net investment cash flow.

The current PE ratio is 15.3, and the trailing PE ratio has dropped to 13.7. Due to the current profit level being only in the tens of millions, it is advisable to choose cautiously (⭐️).